The National Institute for Health and Clinical Excellence (NICE) has reported that the NHS will not fund the anti-cancer drug Avastin in England and Wales.
It is used to fight late stage bowel cancer and research shows the drug can extend life an extra six weeks.

About 6,500 people per year would benefit from the drug.

Since the drug cost £21,000 for a year of treatment, the health watchdog has labelled it as too expensive.